Nelly delivered a decent Q4 report in our view with c.
Redeye updates its estimates and valuation following MedCap’s Q4 2025 report.
Redeye updates its view following CTEK’s Q4 report.
* A solid report and new targets underpin long-term case * Adj.
Q4 showed a long-awaited return to organic growth driven by sales in Europe, while sales in the Amer...
* Cost actions showing up in margin improvements * Memory prices could support near-term growth reco...
Arctic Minerals har efter förvärvet av Rare Earth Energy Metals positionerat sig som ett nordiskt ko...
Actic has delivered an impressive turnaround, driven by good execution and greater efficiency.
Redeye comments on Faron’s announcement of a planned fully pre-emptive rights issue of approximately...
Solteq reports Q4 figures on February 12. Despite a December guidance cut and change negotiations an...
* Sales of SEK 432m, organic decline of 2% * Adj. EBITA of SEK 35m, and a margin of 8% * Continued d...
Redeye provides an initial comment on the Q4 2025 report from Sdiptech, where adjusted EBITA in core...
Redeye provides an initial take following the release of Optomed’s Q4 2025 report.
Nelly Group Q4 report was solid but mixed, with net sales of SEK 371m, up 16% y/y (5% ahead of SEB),...
* 0%/-3% adj. EBITDA vs ABGSCe/Infront cons in Q4 * Cons estimates likely flat on adj.
Enersense and Finnish energy company Helen have agreed to extend their operations and maintenance ag...
Inderes's Q4 profitability was slightly ahead of our estimate, owing to slightly better than expecte...
Relais outperformed the market in Q3 and we expect a similar performance for Q4.
Investors House's Q4 report was solid, with the Services segment surprising positively, while the Re...
Redeye provides a preview of Catella ahead of the company's Q4 2025 results, scheduled for 17 Februa...
